| Patent Number |
Title Of Patent |
Date Issued |
| 6432381 |
Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract |
August 13, 2002 |
| Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect. |
| 6221400 |
Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus ( |
April 24, 2001 |
| The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio v |
| 6068858 |
Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease in |
May 30, 2000 |
| The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio v |
| 6045829 |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cel |
April 4, 2000 |
| The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio va |
| 5834025 |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiologica |
November 10, 1998 |
| Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the |
| 5552160 |
Surface modified NSAID nanoparticles |
September 3, 1996 |
| Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit red |
| 5494683 |
Surface modified anticancer nanoparticles |
February 27, 1996 |
| Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles |
| 5451393 |
X-ray contrast compositions useful in medical imaging |
September 19, 1995 |
| An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an |
| 5399363 |
Surface modified anticancer nanoparticles |
March 21, 1995 |
| Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles |
| 5318767 |
X-ray contrast compositions useful in medical imaging |
June 7, 1994 |
| An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an |
| 5302401 |
Method to reduce particle size growth during lyophilization |
April 12, 1994 |
| This invention discloses a composition comprised of nanoparticles having a surface modifier adsorbed on the surface thereof and a cryoprotectant associated therewith, which cryoprotectant is present in an amount sufficient to form a nanoparticle-cryoprotectant composition. A preferred |
| 5145684 |
Surface modified drug nanoparticles |
September 8, 1992 |
| Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and d |
